During the past decade, Essex Oncology of North Jersey conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 2 clinical trials were completed, i.e. on average, 18.2% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Essex Oncology of North Jersey" #1 sponsor was "Celgene" with 2 trials, followed by "Aadi Bioscience, Inc." with 1 trials sponsored, "Achieve Life Sciences" with 1 trials sponsored, "Agendia" with 1 trials sponsored and "Biodesix, Inc." with 1 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Essex Oncology of North Jersey" #1 collaborator was "Amgen" with 1 trials as a collaborator, "Astellas Pharma Inc" with 1 trials as a collaborator, "GlaxoSmithKline" with 1 trials as a collaborator and "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Essex Oncology of North Jersey" are "Breast Cancer" (2 trials), "Metastatic Cancer" (2 trials), "Solid Tumor" (2 trials), "ALK Positive Malignancies" (1 trials) and "Advanced Cancer" (1 trials). Many other conditions were trialed in "Essex Oncology of North Jersey" in a lesser frequency.

Most popular intervention types in "Essex Oncology of North Jersey" are "Drug" (12 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Carboplatin" (2 trials), "paclitaxel" (2 trials), "Albumin-bound paclitaxel" (1 trials), "Amivantamab" (1 trials) and "Blood draw (venipuncture)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Essex Oncology of North Jersey" are 14 trials for "All" genders, 2 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Essex Oncology of North Jersey". undefined are not yet recruiting, 4 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Essex Oncology of North Jersey, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Essex Oncology of North Jersey, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 6 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".